Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Weighted average number of shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Trading Arrangement: Trading Arrangement [Axis] Outstanding, Weighed Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted-Average Remaining Contractual Term Less: amount representing interest Operating And Finance Lease Liability, Undiscounted Excess Amount Operating And Finance Lease Liability, Undiscounted Excess Amount Maximum Maximum [Member] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Statistical Measurement Statistical Measurement [Domain] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Document Fiscal Year Focus Document Fiscal Year Focus Non-cash royalty revenue related to sale of future royalties Non-Cash Royalty Revenue Related To Sale Of Future Royalties Non-Cash Royalty Revenue Related To Sale Of Future Royalties Microchips Biotech, Inc. Microchips Biotech, Inc. [Member] Microchips Biotech, Inc. [Member] Adjustment to Compensation, Amount Adjustment to Compensation Amount Conversion of stock, issued (in shares) Conversion of Stock, Shares Issued Segment Reporting [Abstract] Schedule of Financial Assets and Liabilities Remeasured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Going Concern Liquidity [Policy Text Block] Liquidity Common stock, $0.0001 par value; 240,000,000 shares authorized; 15,169,502 and 14,499,502 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively Common Stock, Value, Issued 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Other indirect costs Other Indirect Costs [Member] Other Indirect Costs Leased Properties Lessee, Finance Leases [Text Block] Restatement Determination Date Restatement Determination Date Class of Warrant or Right Class of Warrant or Right [Domain] 2027 Finance Lease, Liability, to be Paid, Year One Initial payment Grants Receivable License and Collaboration Agreement License And Collaboration Agreement [Member] License And Collaboration Agreement [Member] Amended and Restated 2014 Stock Incentive Plan Amended And Restated Two Thousand Fourteen Stock Incentive Plan [Member] Amended And Restated Two Thousand Fourteen Stock Incentive Plan Amendment Flag Amendment Flag Milestone payments, contingent amount Milestone Payments, Contingent Amount Milestone payments, contingent amount. Current liabilities Liabilities, Current [Abstract] Conversion of stock (in shares) Conversion of Stock, Shares Converted Project [Axis] Project [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Principal payments on financing lease Financing cash flows from finance lease Finance Lease, Principal Payments Class of Warrant or Right [Table] Class of Warrant or Right [Table] Pear Tree Pharmaceuticals, Inc. Pear Tree Pharmaceuticals, Inc. [Member] Pear Tree Pharmaceuticals, Inc. December 2023 Warrants December 2023 Warrants [Member] December 2023 Warrants Leases [Abstract] Leases [Abstract] Number of non-employee directors Number Of Non-Employee Directors Number Of Non-Employee Directors March 2023 At The Market Sales Agreement March 2023 At The Market Sales Agreement [Member] March 2023 At The Market Sales Agreement Preferred stock, convertible, public offering, share price trigger Preferred Stock, Convertible, Public Offering, Share Price Trigger Preferred Stock, Convertible, Public Offering, Share Price Trigger Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Entity Address, State or Province Entity Address, State or Province Licensing Agreements Licensing Agreements [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross PEO Total Compensation Amount PEO Total Compensation Amount Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Contra R&D expenses Contra Research And Development Expense, Indirect Costs Contra Research And Development Expense, Indirect Costs Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Grant, DARE-PTB1 Grant, DARE-PTB1 [Member] Grant, DARE-PTB1 Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Entity Address, City or Town Entity Address, City or Town Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Receivables [Abstract] Receivables [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Royalty payments Payments for Royalties Level 2 Fair Value, Inputs, Level 2 [Member] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Underlying Awards Granted Under the Amended 2014 Plan Underlying Awards Granted Under the Amended Two Thousand Fourteen Plan [Member] Underlying Awards Granted Under the Amended Two Thousand Fourteen Plan Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Amount awarded for grant Proceeds From Award Of Grants Proceeds From Award Of Grants License License [Member] Net proceeds from issuance of Series A Convertible Preferred Stock and warrants in connection with Regulation A financing Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants Subsequent Event Type Subsequent Event Type [Axis] Research and development funding percentage Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred, For General And Administrative Expenses, Percentage Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred, For General And Administrative Expenses, Percentage Cash flow from operations Cash Provided by (Used in) Operating Activity, Continuing Operation Recently Issued Accounting Pronouncements Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Finance lease, incremental borrowing rate, prime rate Finance Lease, Incremental Borrowing Rate, Prime Rate Finance Lease, Incremental Borrowing Rate, Prime Rate Schedule of Segment Reporting Information, by Segment Segment Reporting [Table Text Block] Common stock issuable upon exercise or conversion of the securities underlying the Agent Units Selling Agent Unit Warrants [Member] Selling Agent Unit Warrants License and services agreement term License And Services Agreement, Term License And Services Agreement, Term Use of Estimates Use of Estimates, Policy [Policy Text Block] Related Party Related and Nonrelated Parties [Axis] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Exercise price (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Preferred stock, convertible, share price trigger Preferred Stock, Convertible, Share Price Trigger Preferred Stock, Convertible, Share Price Trigger Schedule of Operating Lease Liabilities Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Document Period End Date Document Period End Date Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Research And Development Services Research And Development Services [Member] Research And Development Services Sales Milestones Sales Milestones [Member] Sales Milestones [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Insurance financing, face amount Debt Instrument, Face Amount Preeclampsia Agreement Preeclampsia Agreement [Member] Preeclampsia Agreement Stockholders' Equity Equity [Text Block] Security Exchange Name Security Exchange Name National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell [Member] National Collegiate Inventors And Innovators Alliance, Inc. d/b/a VentureWell Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Additional investment amount Class Of Warrant Or Right, Supplement Investment Class Of Warrant Or Right, Supplement Investment Beneficial ownership percentage Beneficial Ownership Percentage Beneficial Ownership Percentage Weighted-average remaining lease term, finance leases (in years) Finance Lease, Weighted Average Remaining Lease Term Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Shell Company Entity Shell Company Consolidation Items [Domain] Consolidation Items [Domain] Total research and development direct program costs Research And Development Expense, Direct Program Costs, Net Research And Development Expense, Direct Program Costs, Net Upon Achieving Certain Commercial Milestones Upon Achieving Certain Commercial Milestones [Member] Upon Achieving Certain Commercial Milestones [Member] Options to purchase number of outstanding shares of common stock (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Current portion of lease liabilities, operating Operating Lease, Liability, Current Finance lease payment due included in accounts payable Finance Lease Payment Due Included In Accounts Payable Finance Lease Payment Due Included In Accounts Payable Foundation Foundation [Member] Foundation Segment Information Segment Reporting, Policy [Policy Text Block] Class of warrant or right, extent holder own percentage (more than) Class of Warrant or Right, Extent Holder Own Percentage Class of Warrant or Right, Extent Holder Own Percentage Finance lease right-of-use asset Finance Lease, Right-of-Use Asset, after Accumulated Amortization Net Loss Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Earnings Per Share [Abstract] Earnings Per Share [Abstract] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Commission percent Percentage Of Aggregate Commission Percentage of aggregate commission. Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Total liabilities Liabilities Trading Symbol Trading Symbol Initial award amount Proceeds From Award Of Grants, Initial Amount Proceeds From Award Of Grants, Initial Amount Convertible preferred stock, shares issued upon conversion Convertible Preferred Stock, Shares Issued upon Conversion Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Preferred stock, convertible, threshold consecutive trading days Preferred Stock, Convertible, Threshold Consecutive Trading Days Preferred Stock, Convertible, Threshold Consecutive Trading Days Company Selected Measure Name Company Selected Measure Name Sale of Stock Sale of Stock [Domain] Royalty Purchase Agreement Royalty Purchase Agreement [Member] Royalty Purchase Agreement Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Upon Achieving Certain Clinical and Regulatory Development Milestones Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Upon Achieving Certain Clinical And Regulatory Development Milestones [Member] Authorized amount (up to) Sale Of Stock, Authorized, Amount Sale Of Stock, Authorized, Amount Contraceptive Landscape Review Agreement Contraceptive Landscape Review Agreement [Member] Contraceptive Landscape Review Agreement Related Party Transactions [Abstract] Proceeds from royalties received Upfront payment from the sale of future royalties Proceeds from Royalties Received Number of additional payment Royalty Agreement, Number Of Additional Payments Royalty Agreement, Number Of Additional Payments Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Common stock warrants Warrant [Member] Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Accounts, Notes, Loans and Financing Receivable [Line Items] Accounts, Notes, Loans and Financing Receivable [Line Items] Proceeds from sale of royalty and milestone rights Proceeds From Sale Of Royalty And Milestone Rights Proceeds From Sale Of Royalty And Milestone Rights Sales based milestones amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Milestone Payments, Contingent Amount, Sales Based Milestones Amount Entity Emerging Growth Company Entity Emerging Growth Company Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Advanced written notice period Upfront License Fee, Advanced Written Notice, Period Upfront License Fee, Advanced Written Notice, Period Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent September 2023 Warrants September 2023 Warrants [Member] September 2023 Warrants Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Less: amount representing interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Bayer Bayer Healthcare LLC [Member] Bayer Healthcare LLC Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Prepaid expenses Prepaid Expense Transaction costs Sale Of Royalty And Milestone Rights, Net Of Transaction Costs Sale Of Royalty And Milestone Rights, Net Of Transaction Costs Other non-current assets Increase (Decrease) in Other Noncurrent Assets Other receivables Other Receivables Less: amount representing interest Finance Lease, Liability, Undiscounted Excess Amount Cash, Cash Equivalents, and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Operating cash flows from operating leases Operating Lease, Payments Award Timing Predetermined Award Timing Predetermined [Flag] Sale of stock, reimbursed and reimbursable issuance costs Sale Of Stock, Reimbursed And Reimbursable Issuance Costs Sale Of Stock, Reimbursed And Reimbursable Issuance Costs Project [Domain] Project [Domain] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Level 1 Fair Value, Inputs, Level 1 [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Total lease payments Lessee, Operating Lease, Liability, to be Paid Agent Unit Warrants Agent Unit Warrants [Member] Agent Unit Warrants Granted (in shares) Outstanding at beginning of period (in usd per share) Outstanding at end of period (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Liability related to the sale of future royalties Royalty Guarantees, Commitments, Gross Amount Royalty Guarantees, Commitments, Gross Amount All Executive Categories All Executive Categories [Member] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Personnel-related (including stock-based compensation) Personnel-Related (Including Stock Based Compensation) [Member] Personnel-Related (Including Stock Based Compensation) Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Plan Name Plan Name [Domain] Antidilutive Securities Antidilutive Securities [Axis] Outstanding beginning balance (in usd per share) Outstanding ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Number of Shares Underlying Warrants Number of RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the consolidated balance sheets: Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Non-dilutive grant funding, percentage excluded Non-Dilutive Grant Funding, Percentage Excluded Non-Dilutive Grant Funding, Percentage Excluded Non-cash interest expense and interest payable associated with the sale of future royalties Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties Non-Cash Interest Expense On Liability Related To Sale Of Future Royalties Preferred stock, convertible, conversion price Preferred Stock, Convertible, Conversion Price Renewal term of operating lease Lessee, Operating Lease, Renewal Term Debt Instrument, Name Debt Instrument, Name [Domain] Former Stockholders of MBI Former Stockholders of MBI [Member] Former Stockholders of MBI Research and development services and royalty revenue Royalty [Member] Other advanced clinical stage programs Other Advanced Clinical Stage Programs [Member] Other Advanced Clinical Stage Programs Sildenafil Cream, 2.0% Sildenafil Cream, 2.0% [Member] Sildenafil Cream, 2.0% Segment Information Segment Reporting [Text Block] Minimum Minimum [Member] Expiration Date Trading Arrangement Expiration Date Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments and contingencies. Underlying Awards Granted 2022 Stock Incentive Plan Underlying Awards Granted Two Thousand Twenty Two Stock Incentive Plan [Member] Underlying Awards Granted Two Thousand Twenty Two Stock Incentive Plan Merger Agreement Merger Agreement [Member] Merger Agreement Class of Warrant or Right Class of Warrant or Right [Axis] Effect of exchange rate changes on cash and cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement Location Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure DARE-HPV DARE-HPV [Member] DARE-HPV 2026 (remaining) Operating And Finance Lease Liability Payments Remainder of Fiscal Year Operating And Finance Lease Liability Payments Remainder of Fiscal Year Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Payments on note payable Repayments of Notes Payable Additions to property and equipment included in accrued expense Additions To Property And Equipment Included In Accrued Expenses And Accounts Payable Additions To Property And Equipment Included In Accrued Expenses And Accounts Payable Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Net proceeds from issuance of common stock Proceeds from Issuance of Common Stock Common stock, shares authorized (in shares) Common Stock, Shares Authorized Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and contingencies. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Series A Convertible Preferred Stock Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock Sale of stock, number of shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Working capital Working Capital Increase (Deficit) Working Capital Increase (Deficit) Schedule of RSU Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Future net sales Royalty Agreement, Future Net Sales, Percentage Royalty Agreement, Future Net Sales, Percentage Exercise Price Award Exercise Price Related Party Transaction [Axis] Related Party Transaction [Axis] Segment Reporting [Line Items] Segment Reporting [Line Items] Royalty Purchase Agreements Royalty Purchase Agreements [Text Block] Royalty Purchase Agreements Document Quarterly Report Document Quarterly Report Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Segments [Domain] Segments [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Milestone payments, reimburse amount, PDUFA fees and other manufacturing expenses Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses Milestone Payments, Reimburse Amount, PDUFA Fees and Other Manufacturing Expenses Total lease payments Operating And Finance Lease Liability Payments Due Operating And Finance Lease Liability Payments Due Debt issuance cost Debt Issuance Costs, Net Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Lease Contractual Term [Axis] Lease Contractual Term [Axis] Other receivables Increase (Decrease) in Other Receivables Supplemental investment (in shares) Class Of Warrant Or Right, Supplement Investment Share Amount Class Of Warrant Or Right, Supplement Investment Share Amount 2014 Employee Stock Purchase Plan Two Thousand And Fourteen Employee Stock Purchase Plan [Member] Two thousand and fourteen employee stock purchase plan. Equity Component [Domain] Equity Component [Domain] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Aggregate gross proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Adoption Date Trading Arrangement Adoption Date Weighted-average discount rate, finance leases Finance Lease, Weighted Average Discount Rate, Percent Unamortized stock-based compensation expense Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent Schedule of Supplemental Cash Flows Information Related to Leases Schedule Of Supplemental Cash Flows Information Related To Leases [Table Text Block] Schedule Of Supplemental Cash Flows Information Related To Leases Note annual interest rate Debt Instrument, Interest Rate, Stated Percentage Insurance Financing Insurance Financing [Member] Insurance Financing XOMA XOMA (US) LLC [Member] XOMA (US) LLC Counterparty Name [Domain] Counterparty Name [Domain] Total stockholders' (deficit) equity Beginning balance Ending balance Equity, Attributable to Parent Performance period Research And Development Arrangement, Performance Period Research And Development Arrangement, Performance Period Write-off of deferred offering costs Deferred Debt Issuance Cost, Writeoff Weighted average amortization period Weighted Average Amortization Period Weighted Average Amortization Period Assets Assets [Abstract] Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] 2027 Operating And Finance Lease Liability Payments Due Year One Operating And Finance Lease Liability Payments Due Year One Present value of lease liabilities Operating Lease, Liability Payments of stock issuance costs Payments of Stock Issuance Costs Number of services agreements Collaborative Arrangement and Arrangement Other than Collaborative, Number Of Services Agreements Collaborative Arrangement and Arrangement Other than Collaborative, Number Of Services Agreements Insider Trading Policies and Procedures [Line Items] Present value of lease liabilities Finance Lease, Liability Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Selling, general and administrative Selling, General and Administrative Expense Direct program costs: Research And Development Direct Program Costs [Abstract] Research And Development Direct Program Costs Business Combination Business Combination [Domain] Digital Offering, LLC Digital Offering, LLC [Member] Digital Offering, LLC Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Antidilutive securities excluded from computation of diluted weighted-average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Number of operating segments Number of Operating Segments Common stock issuable upon settlement of restricted stock units Restricted Stock Units (RSUs) [Member] Schedule of Potential Dilutive Outstanding Securities Excluded From Diluted Net Loss Per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Entity Central Index Key Entity Central Index Key Maximum royalty payments Royalty Agreement, Maximum Royalty Payments Royalty Agreement, Maximum Royalty Payments Milestone payments Research And Development Milestone Payment Research and development milestone payment. All Adjustments to Compensation All Adjustments to Compensation [Member] Business Combination Business Combination [Axis] Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Preferred stock, liquidation preference Preferred Stock, Liquidation Preference, Value Deferred grant funding Deferred Grant Funding, Current Deferred Grant Funding, Current Indirect costs: Research And Development Expense, Indirect Costs Research And Development Expense, Indirect Costs Income Statement [Abstract] Income Statement [Abstract] Stockholders' (deficit) equity Equity, Attributable to Parent [Abstract] Document Transition Report Document Transition Report Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Operating expenses Segment operating expenses: Operating Expenses [Abstract] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Preferred Stock Preferred Stock, Redeemable [Policy Text Block] Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] October 2016 Warrants October 2016 Warrants [Member] October 2016 Warrants City Area Code City Area Code Assignment Agreement Assignment Agreement [Member] Assignment Agreement [Member] Total lease payments Finance Lease, Liability, to be Paid Restricted Stock Restricted Stock [Member] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Subsequent Events Subsequent Events [Text Block] Collaborative Arrangement Collaborative Arrangement [Member] Name Forgone Recovery, Individual Name Remaining weighted-average service period (in months) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted Average Exercise Price Weighted-Average Grant-Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Statement [Line Items] Statement [Line Items] Research and development: Research and Development Expense [Abstract] Total assets Assets Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Entity Entity [Domain] Credits recorded to research and development expense for costs related to award Research and Development Arrangement with Federal Government, Customer Funding to Offset Costs Incurred Receivable for expenses eligible for reimbursement Receivable For Expenses Eligible For Reimbursement Receivable For Expenses Eligible For Reimbursement Weighted Average Remaining Life in Years Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Common stock reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Interest expense Interest Expense, Nonoperating Weighted-average fair value of options granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Preclinical stage programs Preclinical Stage Programs [Member] Preclinical Stage Programs Purchase commitment, maximum amount committed Purchase Commitment, Maximum Amount Committed Purchase Commitment, Maximum Amount Committed Number of lowest sale prices Number Of Lowest Sale Prices Number Of Lowest Sale Prices Schedule of Recognized Stock-Based Compensation Expense Related to Stock Options Granted to Employees and Directors Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Present value of lease liabilities Operating And Finance Lease Liability Operating And Finance Lease Liability Right to receive (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Right To Receive Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Right To Receive Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period, Shares, New Issues PEO PEO [Member] Prepaid expenses Increase (Decrease) in Prepaid Expense Expired (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Expense Sildenafil Cream Sildenafil Cream, 3.6% [Member] Sildenafil Cream, 3.6% Measurement Basis [Axis] Measurement Basis [Axis] Quarterly payment period Royalty Agreement, Quarterly Payments, Period Royalty Agreement, Quarterly Payments, Period Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value DARE-LARC1 DARE-LARC1 [Member] DARE-LARC1 Clinical and Regulatory Milestones Clinical And Regulatory Milestones [Member] Clinical And Regulatory Milestones [Member] Subsequent Event Type Subsequent Event Type [Domain] Accumulated deficit Retained Earnings [Member] Lease liabilities long-term, operating Operating Lease, Liability, Noncurrent Net proceeds from sale of stock Sale Of Stock, Consideration Received On Transaction, Net Of Commissions Sale Of Stock, Consideration Received On Transaction, Net Of Commissions Total operating expenses Operating Expenses Forfeited (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Series A Preferred Stock Series A Preferred Stock [Member] Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Canceled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Award Timing Disclosures [Line Items] Loss per common share - diluted (in usd per share) Earnings Per Share, Diluted Entity Current Reporting Status Entity Current Reporting Status Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Series A Convertible Preferred Stock Series A Non Voting Convertible Preferred Stock [Member] Series A Non Voting Convertible Preferred Stock Total Shareholder Return Amount Total Shareholder Return Amount Incremental borrowing rate, amount over prime rate Operating Lease, Incremental Borrowing Rate, Prime Rate Operating Lease, Incremental Borrowing Rate, Prime Rate Internal rate of return Royalty Agreement, Internal Rate Of Return Royalty Agreement, Internal Rate Of Return Preferred stock, initial stated value per share Preferred Stock, Initial Stated Value Per Share Preferred Stock, Initial Stated Value Per Share Upon Reaching Certain Worldwide Net Sales Milestones Upon Reaching Certain Worldwide Net Sales Milestones [Member] Upon reaching certain worldwide net sales milestones. Right-of-use assets - operating lease Increase (Decrease) In Operating Lease Right-of-Use Asset Increase (Decrease) In Operating Lease Right-of-Use Asset Preferred stock, convertible, threshold trading days Preferred Stock, Convertible, Threshold Trading Days Preferred Stock, Convertible, Threshold Trading Days Regulation A Offering Regulation A Offering [Member] Regulation A Offering Research and development Total research and development Research and Development Expense Lease Contractual Term [Domain] Lease Contractual Term [Domain] Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] United in Endeavor, LLC United in Endeavor, LLC [Member] United in Endeavor, LLC Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Property and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Upon Achieving Certain Development Milestones Upon Achieving Certain Development Milestones [Member] Upon Achieving Certain Development Milestones [Member] Variable lease cost Variable Lease, Payment Shares issued (in usd per share) Shares Issued, Price Per Share Contra-R&D expenses Contra-R&D expenses Contra Research And Development Expense, Direct Program Costs Contra Research And Development Expense, Direct Program Costs Maximum potential milestone payments Maximum Potential Milestone Payments Maximum Potential Milestone Payments Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Underlying Securities Award Underlying Securities Amount Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Percentage of royalty rate Royalty Rate, Percentage Royalty Rate, Percentage Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Interest payable Increase (Decrease) in Interest Payable, Net Other current assets Prepaid Expense, Current Canceled/forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Preferred stock, convertible, public offering proceeds, trigger Preferred Stock, Convertible, Public Offering Proceeds, Trigger Preferred Stock, Convertible, Public Offering Proceeds, Trigger Common stock issuable upon conversion of Series A Preferred Stock Preferred Stock [Member] Phase II Segment Phase II Segment [Member] Phase II Segment MBI MBI [Member] MBI Convertible preferred stock, shares reserved for future issuance Convertible Preferred Stock, Shares Reserved for Future Issuance Weighted-average discount rate, operating leases Operating Lease, Weighted Average Discount Rate, Percent Catalent and MilanaPharm Catalent and MilanaPharm [Member] Catalent and MilanaPharm Segment Reporting [Table] Segment Reporting [Table] Potential annual license maintenance fee payments, thereafter Potential Annual License Maintenance Fee Payments, Thereafter Potential Annual License Maintenance Fee Payments, Thereafter Issuance of Series A Convertible Preferred Stock and warrants in connection with Regulation A financing, net of issuance costs Issuance Of Series A Convertible Preferred Stock And Warrants, Value Issuance Of Series A Convertible Preferred Stock And Warrants, Value Liability related to the sale of future royalties, net Royalty Guarantees, Commitments, Amount Sale of Stock Sale of Stock [Axis] Cash flows from investing activities Cash Provided by (Used in) Investing Activity, Continuing Operation [Abstract] Schedule of Lease Cost Lease, Cost [Table Text Block] Other receivables Other Assets, Current Cash flows from operating activities Cash Provided by (Used in) Operating Activity, Continuing Operation [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Loss from operations Loss from operations Operating Income (Loss) Current Fiscal Year End Date Current Fiscal Year End Date Schedule of Finance Lease Liabilities Maturity Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Warrants and rights outstanding (in shares) Relative fair value of Initial Royalty Warrant Warrants and Rights Outstanding 2026 (remaining) Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Sale of stock, placement fee, percentage Sale of Stock, Placement Fee, Percentage Sale of Stock, Placement Fee, Percentage Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Related Party Transaction [Domain] Related Party Transaction [Domain] Maximum percentage increase License And Services Agreement, Maximum Fee Increase, Percentage License And Services Agreement, Maximum Fee Increase, Percentage Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Schedule of Common Stock Warrants Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Potential future payment Royalty Agreement, Maximum Potential Milestone Payments Royalty Agreement, Maximum Potential Milestone Payments Issuance cost Offering Cost, Expense Schedule of Stock Option Activity for Amended 2014 Plan and Related Information Share-Based Payment Arrangement, Option, Activity [Table Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Licensed Product or Process for Vaginal or Urological Use Licensed Product or Process for Vaginal or Urological Use [Member] Licensed Product or Process for Vaginal or Urological Use Common stock, shares issued (in shares) Common Stock, Shares, Issued Measure: Measure [Axis] Equity Components [Axis] Equity Components [Axis] Accounts receivable Increase (Decrease) in Accounts Receivable Related Party Related Party [Member] Product and Service [Domain] Product and Service [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Entity Interactive Data Current Entity Interactive Data Current Current portion of lease liability, finance Finance Lease, Liability, Current Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Non-cash interest expense Non-Cash Interest Expense Non-Cash Interest Expense Entity Small Business Entity Small Business Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent 2022 Stock Incentive Plan Two Thousand Twenty Two Stock Incentive Plan [Member] Two Thousand Twenty Two Stock Incentive Plan Termination Date Trading Arrangement Termination Date Juniper Pharmaceuticals, Inc Juniper Pharmaceuticals, Inc. [Member] Juniper Pharmaceuticals, Inc. [Member] Potential future payment, percentage Royalty Agreement, Milestone Payments, Sales Based Potential Future Milestones Royalty Agreement, Milestone Payments, Sales Based Potential Future Milestones Subsequent Events [Abstract] Subsequent Events [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Number of proceeding business period Number Of Proceeding Business Period Number Of Proceeding Business Period Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Royalty agreement, estimated amount of royalty obligation Royalty Agreement, Estimated Amount Of Royalty Obligation Royalty Agreement, Estimated Amount Of Royalty Obligation Expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Other non-current assets Other Assets, Noncurrent Cash flows from financing activities Cash Provided by (Used in) Financing Activity, Continuing Operation [Abstract] Document Type Document Type Deferred grant funding Increase (Decrease) In Deferred Grant Funding Increase (Decrease) In Deferred Grant Funding Agent Common Warrant Agent Common Warrant [Member] Agent Common Warrant Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Accrued expenses Accrued Liabilities, Current Fair Value as of Grant Date Award Grant Date Fair Value Outstanding, Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Cash paid to stockholders' representative Payments to Stockholders' Representative in Business Combination Payments to Stockholders' Representative in Business Combination Basis of Presentation and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Revenue tier threshold, upper range limit Royalty Agreement, Revenue Tier Threshold, Incremental Amount Royalty Agreement, Revenue Tier Threshold, Incremental Amount Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event [Line Items] Subsequent Event [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Outstanding advances Advances on Inventory Purchases Consolidation Items [Axis] Consolidation Items [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Current portion of contingent consideration Asset Acquisition, Contingent Consideration, Current Asset Acquisition, Contingent Consideration, Current Common stock warrants Common Stock Warrants [Member] Common Stock Warrants Conversion of Series A preferred stock into common stock Conversion of Stock, Type of Stock Converted, Amount Conversion of Stock, Type of Stock Converted, Amount Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Warrant term Warrants and Rights Outstanding, Term Commitments and contingencies (Note 9) Commitments and Contingencies Purchase Agreement Purchase Agreement [Member] Purchase Agreement Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Executive Category: Executive Category [Axis] Royalty Interest Financing Sale Of Future Royalties [Text Block] Sale Of Future Royalties Amortization of finance lease Finance Lease, Right-of-Use Asset, Amortization Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Counterparty Name [Axis] Counterparty Name [Axis] Liabilities and stockholders’ equity (deficit) Liabilities and Equity [Abstract] Total revenue Revenue (True-Up) From Contract With Customer, Excluding Assessed Tax Revenue (True-Up) From Contract With Customer, Excluding Assessed Tax Equity Award Award Type [Domain] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Lincoln Park Capital Fund, LLC Lincoln Park Capital Fund, LLC [Member] Lincoln Park Capital Fund, LLC Total Operating And Finance Lease, Liability [Abstract] Operating And Finance Lease, Liability 2026 (remaining) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Class of warrant or right, outstanding Class of Warrant or Right, Outstanding Level 3 Fair Value, Inputs, Level 3 [Member] Supplemental disclosure of non-cash investing and financing activities: Supplemental Cash Flow Information [Abstract] Convertible notes issued, per share Share Price Royalty Revenue Royalty Revenue [Member] Royalty Revenue PEO Name PEO Name Total research and development indirect costs Research And Development Expense, Indirect Costs, Net Research And Development Expense, Indirect Costs, Net Proceeds from research and development arrangement with federal government Proceeds From Research and Development Arrangement with Federal Government Proceeds From Research and Development Arrangement with Federal Government Accrued expenses Increase (Decrease) in Accrued Liabilities Contingent purchase price payments Royalty Agreement, Contingent Purchase Price Payments Royalty Agreement, Contingent Purchase Price Payments Hard cap rate Royalty Agreement, Hard Cap, Percentage Royalty Agreement, Hard Cap, Percentage Class of warrant or right, percentage common stock ownership after exercise Class of Warrant or Right, Percentage Common Stock Ownership After Exercise Class of Warrant or Right, Percentage Common Stock Ownership After Exercise Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Entity Tax Identification Number Entity Tax Identification Number Legal Entity Legal Entity [Axis] Issuable upon additional investment made number of securities called by warrants Class Of Warrant Or Right, Initial Royalty Warrant Issued Class Of Warrant Or Right, Initial Royalty Warrant Issued Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Exercised (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Total cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Contraceptive Product Grant Agreement Contraceptive Product Grant Agreement [Member] Contraceptive Product Grant Agreement Milestone payments rate Royalty Agreement, Milestone Payments, Percentage Royalty Agreement, Milestone Payments, Percentage Exercised (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Exercised, Weighted Average Grant Date Fair Value Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Clean Room Space Clean Room Space [Member] Clean Room Space Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Non-NEOs Non-NEOs [Member] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Debt Instrument Debt Instrument [Axis] Subsequent Event [Table] Subsequent Event [Table] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Purchase And Registration Rights Agreement Purchase And Registration Rights Agreement [Member] Purchase And Registration Rights Agreement Total lease cost Lease, Cost Direct program costs: Research And Development Expense, Direct Program Costs Research And Development Expense, Direct Program Costs Conversion of Series A Preferred Stock into common stock (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Leased Properties Lessee, Operating Leases [Text Block] Loss per common share - basic (in usd per share) Earnings Per Share, Basic Total current assets Assets, Current Statistical Measurement Statistical Measurement [Axis] Insider Trading Arrangements [Line Items] Cost of revenues Cost of Revenue Award Type Award Type [Axis] Payments of deferred offering costs Payments of Financing Costs Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Ovaprene Ovaprene [Member] Ovaprene Product and Service [Axis] Product and Service [Axis] Preferred stock, percentage of stated value per share Preferred Stock, Percentage Of Stated Value Per Share Preferred Stock, Percentage Of Stated Value Per Share Forfeited or expired (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited And Expired, Weighted Average Grant Date Fair Value Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common stock Common stock warrants Common Stock [Member] Upfront license fee paid Upfront License Fee, Amount Paid Upfront License Fee, Amount Paid Fair Value Measurement [Domain] Fair Value Measurement [Domain] Accounts payable Increase (Decrease) in Other Accounts Payable Operating lease cost Operating Lease, Cost Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Regulation A Offering Investor Warrants Regulation A Offering Investor Warrants [Member] Regulation A Offering Investor Warrants Reclassification of Prior Year Presentation Reclassification, Comparability Adjustment [Policy Text Block] Prepaid rent reclassified to finance lease right-of-use asset Prepaid Rent Reclassified To Finance Lease Right Of Use Asset Prepaid Rent Reclassified To Finance Lease Right Of Use Asset Amount due upon execution License And Services Agreement, Amount Payable Upon Execution License And Services Agreement, Amount Payable Upon Execution Net royalty payments rate Royalty Agreement, Net Royalty Payments, Percentage Royalty Agreement, Net Royalty Payments, Percentage Equity Awards Adjustments Equity Awards Adjustments [Member] Strategic Agreements Collaborative Arrangement Disclosure [Text Block] Supplemental investment payment Royalty Agreement, Supplement Investment Payment Royalty Agreement, Supplement Investment Payment Total liabilities and stockholders' (deficit) equity Liabilities and Equity Stock options Share-Based Payment Arrangement, Option [Member] Segments [Axis] Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Plan Name Plan Name [Axis] Related Party Related and Nonrelated Parties [Domain] Tabular List, Table Tabular List [Table Text Block] Restricted cash included in other non-current assets Restricted Cash and Cash Equivalent, Noncurrent Additional paid-in capital Additional Paid in Capital Square footage of office space Net Rentable Area Hennepin License Agreement Hennepin License Agreement [Member] Hennepin License Agreement Grant Awards Grant Award [Text Block] Grant Award [Text Block] Other (expense) income Other income, net Other Nonoperating Income (Expense) Transaction price allocated to remaining performance obligations Transaction Price Allocated To Remaining Performance Obligations Transaction Price Allocated To Remaining Performance Obligations First commercial sale amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Milestone Payments, Contingent Amount, First Commercial Sale Amount Name Awards Close in Time to MNPI Disclosures, Individual Name Schedule of Changes in the Liability Related to the Sale of Future Royalties Schedule Of Changes In The Liability Related To The Sale Of Future Royalties [Table Text Block] Schedule Of Changes In The Liability Related To The Sale Of Future Royalties Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Sale of stock, price per share (in usd per share) Sale of Stock, Price Per Share Conversion of Series A Preferred Stock into common stock Stock Issued During Period, Value, Conversion of Convertible Securities Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, $0.01 par value, 5,000,000 shares authorized; 4,999,620 and 0 designated Series A Convertible Preferred Stock at June 30, 2026 and December 31, 2025, respectively; 75,900 and 0 issued and outstanding at June 30, 2026 and December 31, 2025, respectively. Liquidation preference of $0.4 million and $0 at June 30, 2026 and December 31, 2025, respectively Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Forfeited or expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Repayment period on outstanding advances Outstanding Advances, Repayment Period Outstanding Advances, Repayment Period Class of Stock [Domain] Class of Stock [Domain] Upon Achievement of Specified Development and Regulatory Milestones Upon Achievement Of Specified Development And Regulatory Milestones [Member] Upon achievement of specified development and regulatory milestones. Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Interest on finance lease liability Operating cash flows from finance lease Finance Lease, Interest Payment on Liability Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Phase 1 and Phase 1-ready clinical stage programs Phase 1 And Phase 1-Ready Clinical Stage Programs [Member] Phase 1 And Phase 1-Ready Clinical Stage Programs Warrants Warrants [Member] Warrants Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Name Measure Name Federal Subaward Federal Subaward [Member] Federal Subaward Current portion of liability related to the sale of future royalties Royalty Guarantees Commitments, Liability Related To Sale, Current Royalty Guarantees Commitments, Liability Related To Sale, Current Accounts payable Accounts Payable, Current Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Commitments and Contingencies Commitments Disclosure [Text Block] Other current assets Increase (Decrease) in Other Current Assets XACIATO XACIATO [Member] XACIATO Synthetic Synthetic [Member] Synthetic Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Additional paid-in capital Additional Paid-in Capital [Member] Entity Filer Category Entity Filer Category Preferred stock, non-compounded rate of return, percentage Preferred Stock, Non-Compounded Rate Of Return, Percentage Preferred Stock, Non-Compounded Rate Of Return, Percentage Schedule of Weighted Average Remaining Lease Terms and Discount Rates Weighted Average Remaining Lease Terms And Discount Rates [Table Text Block] Weighted Average Remaining Lease Terms And Discount Rates Name Trading Arrangement, Individual Name Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalent Finance Lease Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Company Selected Measure Amount Company Selected Measure Amount Quantity of warrants outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Depreciation and amortization Depreciation, Depletion and Amortization Entity Address, Address Line Two Entity Address, Address Line Two Schedule of Accounts, Notes, Loans and Financing Receivable [Table] Accounts and Financing Receivables [Table] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Financing right-of-use assets obtained in exchange for new financing lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Indirect cost allowance percentage Grant Awards, Indirect Cost Allowance, Percentage Grant Awards, Indirect Cost Allowance, Percentage Current assets Assets, Current [Abstract] Weighted-average remaining lease term, operating leases (in years) Operating Lease, Weighted Average Remaining Lease Term Non-PEO NEO Non-PEO NEO [Member] Entity Address, Address Line One Entity Address, Address Line One Remeasurement of operating lease right-of-use assets and lease liabilities due to lease modification Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Vested (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Award Timing Method Award Timing Method [Text Block] Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Reportable Segment Reportable Segment [Member] Reportable Segment Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Issuance of Series A Convertible Preferred Stock and warrants in connection with Regulation A financing, net of issuance costs (in shares) Issuance Of Series A Convertible Preferred Stock And Warrants, Shares Issuance Of Series A Convertible Preferred Stock And Warrants, Shares ADVA Tec Agreement A D V A Tec Agreement [Member] ADVA Tec agreement. Net loss Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Investor Warrants Investor Warrants [Member] Investor Warrants Location, Statement of Financial Position, Balance [Axis] Location, Statement of Financial Position, Balance [Axis] Statement [Table] Statement [Table] Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member] Douglas License Agreement Douglas License Agreement [Member] Douglas License Agreement Effective annual interest rate Royalty Agreement, Effective Annual Interest Rate, Percentage Royalty Agreement, Effective Annual Interest Rate, Percentage Restatement Determination Date: Restatement Determination Date [Axis] Indirect costs: Research And Development Indirect Costs [Abstract] Research And Development Indirect Costs Class of warrant or right, number of securities called by each warrant or right (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Stock options Stock Options [Member] Stock Options Interest income Investment Income, Interest Exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Sale of stock, percentage of warrants issuable Sale Of Stock, Percentage Of Warrants Issuable Sale Of Stock, Percentage Of Warrants Issuable Organon Organon [Member] Organon Revenue Revenue: Revenues [Abstract] Payment of additional consideration Payment of Additional Consideration in Business Combination Payment of Additional Consideration in Business Combination Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block]